BCD-261 not checked
Biocad · anti-TL1A · anti-TL1A monoclonal antibody
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes”In the company’s words, NCT06715540 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis (UC), Crohn's Disease (CD)
- Main trialPhase 2
- “The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients with moderate to severe active ulcerative colitis. The study will be conducted in a population of male and female subjects ≥18 years and ≤75 years with moderate to severe active ulcerative colitis and an inadequate response to prior treatment with glucocorticoids, immunosuppressants, or biologics/targeted immunosuppressants.”In the company’s words, NCT07080034 on ClinicalTrials.gov
- Other names
- anti-TL1A · anti-TL1A monoclonal antibody
Other drugs for Ulcerative Colitis (UC)
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJanssen Research & Development, LLC · Phase 3
- IcotrokinraJanssen Research & Development, LLC · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up2
- Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jan 2027 | Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis | |
| Phase 2Recruiting | May 2027 | Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease | |
| Phase 1Recruiting | Feb 2025 | Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026